Gilead Sciences and LEO Pharma have agreed a strategic partnership to accelerate the development of LEO Pharma’s small molecule STAT6 programmes for inflammatory diseases. STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signalling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD. Targeting […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!